Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Nuvectis Pharma, Inc. Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference September 05, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference May 16, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines April 08, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting March 19, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Nuvectis Pharma to Present at the 36th Annual Roth Conference March 15, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer March 14, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences February 09, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Nuvectis Pharma Announces Participation at Upcoming Investor Conferences February 09, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 03, 2024 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholangiocarcinoma December 18, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer October 24, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation September 25, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900 September 21, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial September 12, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900 September 06, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Nuvectis Pharma Announces Participation at Upcoming Investor Conferences September 01, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma August 17, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes June 20, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Nuvectis Pharma Announces FDA Clearance of NXP900 IND May 15, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference April 27, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference April 27, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800's Activity in Cholangiocarcinoma PDX Models at the 2023 American Association for Cancer Research (“AACR”) Annual Meeting April 18, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma April 10, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting March 17, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference March 10, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800 at the 2023 ESMO Gynecological Cancers Congress February 23, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Nuvectis Pharma Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States January 04, 2023 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma December 01, 2022 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Nuvectis Pharma, Inc. to Present at the Roth Inaugural Healthcare Opportunities Conference October 03, 2022 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Nuvectis Pharma Announces Formation of a Scientific Advisory Board September 28, 2022 From Nuvectis Pharma, Inc. Via GlobeNewswire Tickers NVCT Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.